160 related articles for article (PubMed ID: 36573284)
1. Proton Pump Inhibitor Use and Risks of Cardiovascular Disease and Mortality in Patients With Type 2 Diabetes.
Geng T; Chen JX; Zhou YF; Lu Q; Wan Z; Liu L; Pan A; Liu G
J Clin Endocrinol Metab; 2023 May; 108(6):e216-e222. PubMed ID: 36573284
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitor use by aspirin-treated coronary artery disease patients is not associated with increased risk of cardiovascular events.
Fortuna LA; Pawloski PA; Parker ED; Trower NK; Kottke TE
Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):13-9. PubMed ID: 27533057
[TBL] [Abstract][Full Text] [Related]
3. Proton Pump Inhibitor Use and the Risk of Cardiovascular Complications and Death in Older Adults with Diabetes: A Population-Based Cohort Study.
Foresta A; Fernandez LO; Torrigiani G; Schena S; Roncaglioni MC; Nobili A; Tettamanti M; Franchi C; Fortino I; Succurro E; Sesti G; Baviera M
Drugs Aging; 2024 Mar; 41(3):239-249. PubMed ID: 38367169
[TBL] [Abstract][Full Text] [Related]
4. Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction.
Sehested TSG; Gerds TA; Fosbøl EL; Hansen PW; Charlot MG; Carlson N; Hlatky MA; Torp-Pedersen C; Gislason GH
J Intern Med; 2018 Mar; 283(3):268-281. PubMed ID: 29024109
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitor use represents an independent risk factor for myocardial infarction.
Shih CJ; Chen YT; Ou SM; Li SY; Chen TJ; Wang SJ
Int J Cardiol; 2014 Nov; 177(1):292-7. PubMed ID: 25499395
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study.
Shin H; Schneeweiss S; Glynn RJ; Patorno E
Ann Intern Med; 2022 Jul; 175(7):927-937. PubMed ID: 35605236
[TBL] [Abstract][Full Text] [Related]
7. Use of Proton-Pump Inhibitors Predicts Heart Failure and Death in Patients with Coronary Artery Disease.
Pello Lázaro AM; Cristóbal C; Franco-Peláez JA; Tarín N; Aceña Á; Carda R; Huelmos A; Martín-Mariscal ML; Fuentes-Antras J; Martínez-Millá J; Alonso J; Lorenzo Ó; Egido J; López-Bescós L; Tuñón J
PLoS One; 2017; 12(1):e0169826. PubMed ID: 28103324
[TBL] [Abstract][Full Text] [Related]
8. Proton-Pump Inhibitor Use and the Risk of First-Time Ischemic Stroke in the General Population: A Nationwide Population-Based Study.
Wang YF; Chen YT; Luo JC; Chen TJ; Wu JC; Wang SJ
Am J Gastroenterol; 2017 Jul; 112(7):1084-1093. PubMed ID: 28397874
[TBL] [Abstract][Full Text] [Related]
9. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.
Ray WA; Murray KT; Griffin MR; Chung CP; Smalley WE; Hall K; Daugherty JR; Kaltenbach LA; Stein CM
Ann Intern Med; 2010 Mar; 152(6):337-45. PubMed ID: 20231564
[TBL] [Abstract][Full Text] [Related]
10. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY
J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656
[TBL] [Abstract][Full Text] [Related]
11. Proton Pump Inhibitor Use, Hypomagnesemia and Risk of Cardiovascular Diseases: The Atherosclerosis Risk in Communities (ARIC) Study.
Rooney MR; Bell EJ; Alonso A; Pankow JS; Demmer RT; Rudser KD; Chen LY; Lutsey PL
J Clin Gastroenterol; 2021 Sep; 55(8):677-683. PubMed ID: 33471493
[TBL] [Abstract][Full Text] [Related]
12. Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events.
Maret-Ouda J; Santoni G; Xie S; Rosengren A; Lagergren J
Cardiovasc Drugs Ther; 2022 Dec; 36(6):1121-1128. PubMed ID: 34241731
[TBL] [Abstract][Full Text] [Related]
13. Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry.
Hoedemaker NPG; Damman P; Ottervanger JP; Dambrink JHE; Gosselink ATM; Kedhi E; Kolkman E; de Winter RJ; van 't Hof AWJ
Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):127-138. PubMed ID: 30084902
[TBL] [Abstract][Full Text] [Related]
14. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
Goodman SG; Clare R; Pieper KS; Nicolau JC; Storey RF; Cantor WJ; Mahaffey KW; Angiolillo DJ; Husted S; Cannon CP; James SK; Kilhamn J; Steg PG; Harrington RA; Wallentin L;
Circulation; 2012 Feb; 125(8):978-86. PubMed ID: 22261200
[TBL] [Abstract][Full Text] [Related]
15. The Safety of Long-Term Proton Pump Inhibitor Use on Cardiovascular Health: A Meta-Analysis.
Jeridi D; Pellat A; Ginestet C; Assaf A; Hallit R; Corre F; Coriat R
J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887860
[TBL] [Abstract][Full Text] [Related]
16. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitor use and hearing loss in patients with type 2 diabetes: Evidence from a hospital-based case-control study and a population-based cohort study.
Yee J; Han HW; Gwak HS
Br J Clin Pharmacol; 2022 Jun; 88(6):2738-2746. PubMed ID: 34970788
[TBL] [Abstract][Full Text] [Related]
18. Association of Proton Pump Inhibitor Use With All-Cause and Cause-Specific Mortality.
Lo CH; Ni P; Yan Y; Ma W; Joshi AD; Nguyen LH; Mehta RS; Lochhead P; Song M; Curhan GC; Cao Y; Chan AT
Gastroenterology; 2022 Oct; 163(4):852-861.e2. PubMed ID: 35788344
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
[TBL] [Abstract][Full Text] [Related]
20. Association between regular proton pump inhibitors use and cardiovascular outcomes: A large prospective cohort study.
Li ZH; Zhong WF; Qiu CS; Yang P; Song WQ; Shen D; Zhang XR; Liu D; Chen YJ; Chen PL; Huang QM; Chen Q; Wang XM; Chung VCH; Gao X; Kraus VB; Liu SD; Mao C
Int J Cardiol; 2024 Jan; 395():131567. PubMed ID: 37935336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
